72 results about "CD31" patented technology

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

This invention discloses a method for preparing and applying a shell-core composite flexible biomaterial. The flexible biomaterial consists of an outer PMMA electrospun layer, a middle PTFF or PE layer, and a core PEG hydrogel; both the PMMA electrospun layer and the middle layer are porous. This flexible material is soft and elastic, exhibiting good film-forming and osteogenic induction effects. Animal experiments have confirmed that, compared to traditional bone cement, the flexible composite bone cement-induced biofilm shows an increase in CD31-positive cells (representing angiogenesis) and M2 macrophages (representing tissue repair), exhibiting better film-forming properties. It is a promising composite biomaterial that can be widely applied in the treatment of soft tissue defects, bone defects, and bone infections, achieving better therapeutic effects.

The invention discloses an immunohistochemical multi-staining section as well as a preparation method and application thereof, and belongs to the technical field of pathological detection. The multi-staining section is provided with an epithelium-derived malignant tumor staining labeled antibody and a staining labeled antibody of an infringed tissue, the epithelium-derived malignant tumor staining labeled antibody is an AE1 / AE3 antibody, and the staining labeled antibody of the infringed tissue is one or more of an S-100 antibody, a CD31 antibody, a CD34 antibody or an NSE antibody. The section is provided with the overlapped dyeing marks, on one hand, the problem that the requirement for the number of sample sections is high is solved, on the other hand, the invasion relation between epithelium-derived malignant tumor components and nerves and blood vessels can be directly and clearly displayed on one section, and the requirement for accurate diagnosis of pathologists is met.

The invention discloses application of NRP1 protein in preparation of a medicine for promoting angiogenesis and / or healing of a diabetic wound, and belongs to the technical field of biological medicine. The invention provides the application of the NRP1 protein in promoting angiogenesis and healing of the diabetic wound for the first time. The invention discovers that the NRP1 protein can effectively improve the healing disorder problem of diabetic wounds by regulating and controlling angiogenesis and inflammation microenvironment, can significantly enhance the expression of angiogenesis related factors (such as CD31 and CD34), and inhibits the overexpression of proinflammatory factors IL-6 and IL-8; by up-regulating the NRP1 protein level, microangiogenesis can be remarkably promoted, wound repair is accelerated, and meanwhile, the inflammation microenvironment is improved. Related medicaments prepared on the basis of the NRP1 protein can effectively solve the problems of diabetic wound angiogenesis limitation and inflammatory disorder in the prior art, a brand new solution is provided for treatment of diabetic chronic wounds, and the NRP1 protein has remarkable clinical value and application prospects.

The invention belongs to the technical field of biological medicine, and relates to a vascular endothelium targeted bionic nanoparticle and a preparation method and application thereof.The preparation method of the bionic nanoparticle comprises the steps that 1, STM2457 is dissolved, NH2-MSN is added, the mixture is stirred in a dark place, and STMat MSN is obtained; (2) adding the STM (at) MSN and adamantane carboxylic acid into DMF (Dimethyl Formamide) to obtain ade-MSN; (3) adding the ade-MSN into a PBS (Phosphate Buffer Solution), adding beta-CD, and stirring, so as to obtain STM2457 (at) CD-ade-MSN; (4) mixing the liposome with the platelet membrane, and adding the product obtained in the step (3) to obtain STM2457 (at) CD-ade-MSN / PL; and (5) mixing the product in the step (4) with the reduced CD31 antibody to obtain the bionic nanoparticles. The vascular endothelium targeted bionic nanoparticles prepared by the invention can be used for preventing, relieving or / and treating cardiovascular toxicity caused by chemotherapeutic drugs.

The invention relates to the technical field of medicines, in particular to application of an AKT inhibitor targeting FOXO in preparation of a medicine for promoting myocardial ischemic tissue angiogenesis and application of the AKT inhibitor in preparation of a medicine for treating ischemic heart diseases. In the cell level, the AKT inhibitor Ipatasertib can promote migration and tube formation of the HUVEC, and when the 6 [mu] M of Ipatasertib acts on the HUVEC, the expression of AKT can be significantly reduced, and the phosphorylation level of FOXO3 can be inhibited. In an in-vivo experiment, compared with a model group, a mouse in an Ipatasertib intervention group has the advantages that the left ventricular ejection fraction of an echocardiogram is remarkably increased, the myocardial infarction area is remarkably reduced, and the fluorescence density of an angiogenesis marker CD31 + is remarkably increased, so that the Ipatasertib can promote angiogenesis of a myocardial ischemia region of the mouse with acute myocardial infarction and rescue myocardial injury of the mouse.

Methods for producing CD31 + VE-cadherin + KDR + endothelial cells (EC) using chemically defined media are provided, allowing EC production from early mesoderm progenitor cells in a short three days and EC production from pluripotent stem cells in a short five days. Media, isolated cell populations, and kits are also provided.

The invention discloses an antibody combination suitable for detecting DLBCL immune microenvironment by an imaging mass spectrometer, a kit and application. The antibody combination is an antibody for resisting alpha SMA, an antibody for resisting HLADR, an antibody for resisting CD20, an antibody for resisting CD56, an antibody for resisting Vimentin, an antibody for resisting CD8a, an antibody for resisting CCL17, an antibody for resisting CCR6, an antibody for resisting IL3CD123, an antibody for resisting CXCL12, an antibody for resisting BCL2, an antibody for resisting PD1, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting ICOS, an antibody for resisting GranzymeB, an antibody for resisting CXCR5, an antibody for resisting Ki67, an antibody for resisting PDL1, an antibody for resisting Bcl6, an antibody for resisting CD31, an antibody for resisting CD163, an antibody for resisting CD45RO, an antibody for resisting CD27, an And all the antibodies are marked. The DLBCL immune microenvironment can be more comprehensively and efficiently identified by using the antibody combination disclosed by the invention.

The invention provides a periodontal disease tooth root regeneration treatment method and a multi-modal implant system, and relates to the technical field of stomatology and tissue engineering, and the method comprises the following steps: S1, minimally invasive extraction of autologous hDPSCs, CD146 + sorting, co-culture of the autologous hDPSCs, a gradient scaffold and growth factor-loaded microspheres in a dynamic culture device to form an ECM membrane-scaffold complex; s2, minimally invasive implantation of the complex under the guidance of a navigation guide plate, wherein the initial torsion resistance of the magnesium alloy retention nail is larger than or equal to 25 N.cm; s3, zirconium oxide all-ceramic crown repair is carried out 6 months after operation, an adhesive contains 20wt% of nano ZrO, dynamic culture parameters are as follows: 1Hz compressive strain, a double-channel perfusion flow rate ratio is (1: 2)-(1: 4), a culture medium contains 25-50ng / mL of BMP-2 and 5-8ng / mL of USAG-1, and the gradient scaffold has a three-layer pore structure: the porosity of an alveolar bone contact layer is 85 + / -3%. According to the system, a functional periodontal membrane is formed, and collagen fiber bundles are vertically inserted into cementum / bone tissue; the vascularization time is shortened by 50%, and the CD31 + vascular density reaches 28.3 + / -4.7 pieces / mm < 2 > in 14 days after operation.

The invention relates to the technical field of tissue engineering and regeneration, in particular to a stem cell membrane-stent dynamic co-culture device and a gradient regulation culture process. The stem cell membrane-stent dynamic co-culture device comprises a) a multi-modal mechanical loading module (1), a compression strain unit (2) and a multi-modal mechanical loading module (3), the frequency is adjustable from 0.1 Hz to 2 Hz, the strain amplitude is 5%-15% (the precision is + / -0.5%), and the periodic compression stress of bone tissue can be simulated; (2) a fluid shear force unit: generating 0.1-5Pa laminar shear force (Re < 2000) through a conical flow channel (with a taper angle of 15 degrees) and a peristaltic pump, and simulating a shear microenvironment of a blood vessel or periodontal ligament area; the method has the beneficial effects that multi-modal mechanical synergy is achieved, and the cell differentiation efficiency is remarkably improved through coupling loading of compression and shearing force. Experiments show that the ALP activity reaches 38.2 + / -3.1 U / mg (only 12.5 + / -2.3 U / mg in traditional single-mode stimulation), and the proportion of a CD31 + vascularized region is increased to 41.7 + / -3.8% (plt; 0.01).

Provided are a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31 and CD200 and negative for CD45; a cell population substantially consisting of mammalian cells that are positive for cell surface markers CD31, CD157 and CD200 and negative for CD45; a mammalian vascular endothelial stem cell that is positive for the cell surface marker CD31, positive for at least one of CD157 and CD200, and negative for CD45; and a medicament for vascular regeneration, comprising any of the cell populations or the vascular endothelial stem cells as an active ingredient.

The invention relates to the technical field of biological medicine and tissue engineering, in particular to a tissue engineering blood vessel and a preparation method and application thereof. The tissue engineering blood vessel is obtained by modifying interleukin 24 (IL-24) on the surface of an acellular blood vessel, after the tissue engineering blood vessel is transplanted into a body, the number of CD31 + and CD34 + cells can be remarkably increased, and infiltration of M2 type macrophages (CD163 +) on the surface of the blood vessel is remarkably increased; the expression of HIF-1 alpha (hypoxia marker) and MMP9 is obviously reduced; the expression of the nerve specific protein S-100 is obviously increased, thrombosis and intimal hyperplasia are effectively inhibited, and the patency rate of transplanted blood vessels is obviously increased.

The invention belongs to the technical field of medical biomarkers, and particularly relates to application of an antibody to preparation of a marker preparation of a femoral vascular system, the marker preparation of the femoral vascular system is an anti-mouse CD31 antibody used for intravenous injection to a gene animal simultaneously containing Col10a1 gene and Rosa26-tdTomato reporter gene, the Rosa26-tdTomato reporter gene expresses tdTomato, and the Col10a1 gene and the Rosa26-tdTomato reporter gene are used for expressing the TdTomato. A CD31 antibody with a fluorophore is intravenously injected into a blood vessel, and the antibody reaches and marks blood vessels in a thighbone cortical bone, a bone trabecula and a marrow cavity along with blood circulation, so that the goal of three-dimensionally and simultaneously presenting thighbone hypertrophy cartilage cells, progeny cells thereof and a complete blood vessel system is achieved; the limitation that two-dimensional data cannot comprehensively reflect the real situation is broken through, and meanwhile compatibility of tdTomato signals and the transparency technology is achieved.

The present invention belongs to the technical field of monoclonal antibody preparation, and specifically relates to a method for preparing a branched polypeptide that simulates the antigenicity of CD31 linear molecules. The method comprises the following steps: step 1. experimental material preparation; step 2. experimental instrument preparation; step 3. amino acid activation; step 4. amino acid connection to resin; step 5. removal of Fmoc protecting group of amino acid; step 6. peptide resin cleavage; step 7. polypeptide separation; step 8. polypeptide separation, purification and analysis. The invention successfully prepares monoclonal antibodies using branched peptide chains instead of linear peptide chains, which has production significance. This method reduces costs, speeds up preparation, and improves antibody quality. Peptide synthesis only takes a short time. The prepared monoclonal antibodies can be used for WB and IHC experiments, meeting the needs of different antigenic determinants. In short, the monoclonal antibodies prepared by branched peptide chains have the characteristics of precise positioning, low cost, high efficiency and versatility.

The invention relates to a method for simultaneously separating and extracting primary cells of pulmonary vascular endothelium and smooth muscle, and belongs to the technical field of cell culture. The method comprises the following steps: S1, digesting lung vascular tissues by using type I collagenase, and filtering to obtain digested cells; s2, incubating the digestive cells with CD31 magnetic beads to obtain magnetic bead incubated cells; s3, uniformly mixing a buffer solution containing fetal calf serum with the magnetic bead incubation cells, standing, and collecting supernate; s4, adding the supernate into an LS sorting column, collecting negative cells, and culturing with an SMCM complete medium to obtain primary cells of pulmonary vascular smooth muscle; and S5, adding an EGM complete medium into the treated LS sorting column, flushing the cells in the LS sorting column into a culture dish coated with rat tail collagen, and culturing to obtain the primary lung vascular endothelial cells. The primary cells obtained by the method are large in quantity, strong in activity and good in adherence effect; other types of cells are less polluted; economic cost is low, and operation is convenient and fast.

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

Inventors have synthesized peptides allowing an engagement of intact CD31 molecules on all the healthy endothelial cells and resting blood platelets and leukocytes that can enter in contact with an implanted device. Those cells can therefore receive the “leave-me-alone” signal delivered by the trans-homophilic engagement of CD31, which is essential to maintain the homeostasis in the circulation and vascularized tissues. Thrombotic or life-threatening occurrence of hemorrhagic or thromboembolic complications have impaired the use of endovascular devices. The devices bearing the mimicking peptides of the present invention are rapidly integrated, because they are perceived by blood platelets and leukocytes as a healthy endothelium, a “self” component. Furthermore, their ability to be rapidly endothelialized with a physiologic endothelial cell phenotype also limits platelet and leukocyte activation at the site of device implantation in the long-term. Accordingly, the present invention relates to peptides mimicking the trans-homophilic CD31-CD31 domain 1 and 2 intercellular interaction.

The invention discloses a detection reagent and a kit suitable for detecting EB (Epstein-Barr) virus positive DLBCL immune microenvironment by an imaging mass spectrometer. The detection reagent comprises an antibody combination and a probe combination, the antibody combination comprises an anti-alpha SMA antibody, an HLADR antibody, a CD20 antibody, a CD56 antibody, a Vimentin antibody, a CD8a antibody, a CCL17 antibody, a CCR6 antibody, an IL3CD123 antibody, a CXCL12 antibody, a BCL2 antibody, a PD1 antibody, a CD163 antibody, a CD45RO antibody, an ICOS antibody, a GranzymeB antibody, a CXCR5 antibody, a Ki67 antibody, a PDL1 antibody, a Bcl6 antibody, a CD31 antibody, a CD3 antibody, a CD45 antibody, a CD27 antibody, an LAG3 antibody, a PDL2 antibody, a FoxP3 antibody, a CD127 antibody, a CD4 antibody, an EBNA2 antibody, a All antibodies and probes are labeled with metal labels. The EBV + DLBCL immune microenvironment can be more comprehensively and efficiently identified by using the antibody combination or the kit disclosed by the invention.

The present invention provides a method for constructing a sinusoidal network liver organoid and its application, wherein pluripotent stem cells are co-differentiated into HAND1 + Mesoderm and endoderm produce KDR + Mesodermal progenitors give rise to the posterior foregut endoderm, which has CD34 + / CD31 + Endothelial progenitor cells form hepatic endoderm and form a sinusoidal network in liver organoids. These liver organoids possess a functional sinusoidal endothelial network throughout the liver clusters, exhibiting characteristic functions such as low-density lipoprotein uptake, human serum albumin clearance, and secretion of coagulation factor 8. This method provides a new generation of highly biomimetic research tools for understanding liver disease mechanisms, drug screening, and regenerative repair.

A composition for detecting hematopoietic stem cells comprises magnetic beads functionalized with CD34 antibodies, nucleic acid probes bound to CD31 antibodies, nucleic acid probes bound to CD45 antibodies, H1 chains, H2 chains, crRNA and signal nucleic acid chains. When the two probes are fixed to the surface of hematopoietic stem cells, a long chain S is formed. The long chain S acts as an activation chain to open the H1 chain, generating a T / H1 double-stranded structure, thereby exposing the terminal sequence and opening the H2 chain, generating an H1 / H2 double-stranded structure and releasing T, and then proceeding to the next round of hybridization reaction. The end of the H1 / H2 double-stranded structure contains a partial single-stranded structure, which acts as an activation chain to activate the trans-cleavage activity of the CRISPR / cas system, randomly cutting the DNA chain, thereby releasing the terminal MB. The MB molecule can be captured by the hydrophobic cavity of CB[7] to form a stable host-guest complex, generate an electrochemical signal, and realize the detection of hematopoietic stem cells.

The invention belongs to the technical field of biology, and particularly relates to separation and application of proteasome-rich human placenta-derived vascular stem cell outer vesicles. The extracellular vesicles provided by the invention are derived from human placenta source blood vessel promoting stem cells, and the human placenta source blood vessel promoting stem cells show that markers PAI-1 are positive, MECOM is positive, CD201 is positive, CD44 is positive, CD73 is positive, HLA-ABC is positive, CD34 is negative, CD31 is negative and CD326 is negative. Compared with human umbilical cord mesenchymal stem cell outer vesicles, the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes and angiogenic protein factors, wherein the proteasomes have high chymotrypsin-like activity. Moreover, in-vivo and in-vitro experimental data show that the human placenta-derived vascular stem cell outer vesicles provided by the invention are rich in proteasomes, and can degrade accumulation of HIF and inhibit cell apoptosis; the medicine has a treatment effect on myocardial infarction.

The invention belongs to the technical field of thymus immigration cell detection, and particularly relates to a thymus immigration cell marker and application thereof, the marker comprises CD38 used for representing CD4RTE and CD8RTE, the CD38 can be used as a marker for defining thymus RTE, and a system and a kit for detecting the output function of thymus by CD3 + CD4 + CD45RA + CCR7 + CD31 + CD38 + and CD3 + CD8 + CD45RA + CCR7 + CD38 + cells are provided. Compared with the prior art, the thymus output function is detected more quickly and effortlessly, human peripheral CD4RTE can be more accurately defined by detecting the expression of the T cells CD31 and CD38, human peripheral CD8RTE cells can be more accurately defined by detecting the expression of the T cells CD38, and the CD38 can be used as a new surface molecular marker of the CD8RTE. The discovery of the CD8RTE marker supplements the existing theory, and is beneficial to the evaluation of the human thymus senescence function.

The present invention relates to a detection kit for B cells and high endothelial venules in the immune microenvironment of thymus tissue, comprising quantum dot-labeled antibody CD19, quantum dot-labeled antibody CD1d, quantum dot-labeled CD31 and quantum dot-labeled PNad. After the specific antibody coupled with the quantum dot is specifically combined with the antigen on the B cell and high endothelial venule on the tissue section sample, the quantum dot can be used to quantify or locate the B cell and high endothelial venule. Instead of the traditional multicolor immunofluorescence technology, the method of directly carrying specific antibodies with quantum dots is used to save experimental time and improve work efficiency. The expression of B cells and Breg cells in the thymus immune microenvironment and the expression of high endothelial venules can be detected, and at the same time, the relative spatial positions of the above cells and blood vessels can be observed, which directly reflects the state of immune infiltration and autoimmune reaction in the thymus immune microenvironment, and has broad application prospects in the thymus-related immunity and tumor fields.

The invention belongs to the technical field of medicines, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating liver cancer. The traditional Chinese medicine composition is prepared from 12-20 parts of herba epimedii, 2-8 parts of radix dipsaci, 1-5 parts of radix salviae miltiorrhizae, 1-5 parts of rhizoma anemarrhenae, 1-5 parts of fructus psoraleae and 1-5 parts of radix rehmanniae. According to the traditional Chinese medicine composition, expression of CD31 protein, Ki67 protein and Bcl-2 protein in liver cancer cells is reduced, expression of Bax protein, Fas protein and Fast protein in the liver cancer cells is improved, proliferation of the liver cancer cells is inhibited, apoptosis of the liver cancer cells is promoted, and the traditional Chinese medicine composition has a good intervention effect in the aspect of liver cancer treatment.

A noninvasive blood-based biopsy measures surface protein receptors on specific circulating cell populations. Dysregulated quantities of specific surface protein receptors on specific circulating cells indicate the diseased tissue origin. Thus, specific circulating cells serve as proxies for diseased tissue cells as they are shed from such tissues. This approach can be used not only for preeclampsia but also for other vascular disorders where detecting surface protein receptors associated with particular disorders can increase sensitivity and disease specificity. Detection of a high level VEGFR1 on isolated circulating cells that are immunopositive for CD34 and CD31 can be used to identify and treat subjects suffering from preeclampsia.

Methods for generating CD31+VE-cadherin+KDR+ endothelial cells (ECs) are provided using chemically-defined culture media that allow for generating ECs from early mesoderm progenitors in as little as three days and from pluripotent stem cells in as little as five days. Culture media, isolated cell populations and kits are also provided.

The invention discloses a primary endocardial endothelial cell extraction method suitable for cardiovascular disease research. Non-specific components are removed through directional sampling, enzyme digestion and mechanical dispersion of an endocardium microscopic spatula and in combination with a CD31 positive selection and CD36 negative selection combined strategy; after culture, Npr3 backtracking, functional verification and passage limitation (less than or equal to P2) are used for controlling quality. According to the method, the cells with the purity of 80-90%, the motility rate of more than or equal to 85% and stable Npr < 3 + > proportion can be obtained, and compared with a traditional method, the method has the advantages in the aspects of material taking specificity, function fidelity and repeatability. The invention provides a reliable cell source for cardiovascular disease research and transformation application.